FMP
Oct 8, 2021 5:06 PM - Davit Kirakosyan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares dropped more than 45% on Friday following the U.S. Food and Drug Administration’s (FDA) halt on the company’s AlloCAR T clinical trials after the detection of AlloCAR cells with chromosomal abnormality in a single patient treated with ALLO-501A.
Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer of Allogene, said that they will work closely with the FDA to determine the next steps for advancing ALLO-501A. As the company investigates the issue, the analysts at Oppenheimer think that there will be delayed development timelines for key programs including ALLO-501A and ALLO-715, estimating the holds to range from 3 to 6 months.
Following this announcement, the analysts lowered their price target on the company’s shares to $40 from $44, while maintaining their outperform rating.
Sep 11, 2023 - Rajnish Katharotiya
During this post we are going to perform an industry analysis with Python. We will build, analyse and compare all stocks operating within an industry. To do so, we will pick an industry and get all important financial metrics for companies operating in that industry. Then, we will use a couple of fi...
Sep 11, 2023 - Rajnish Katharotiya
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 - Rajnish Katharotiya
Would you like to know how your portfolio is performing and how much risk you are taking? In this post, you will learn how to measure portfolio risk and calculate portfolio returns using Python. We will see step by step how to calculate the risk and returns of a portfolio containing four stocks Appl...